메뉴 건너뛰기




Volumn 114, Issue 3, 2015, Pages 645-650

Two doses of rivaroxaban versus aspirin for prevention of recurrent venous thromboembolism: Rationale for and design of the einstein choice study

(16)  Weitz, Jeffrey I a   Bauersachs, Rupert b   Beyer Westendorf, Jan c   Bounameaux, Henri d   Brighton, Timothy A e   Cohen, Alexander T f   Davidson, Bruce L g   Holberg, Gerlind h   Kakkar, Ajay i   Lensing, Anthonie W A h   Prins, Martin j   Haskell, Lloyd k   Van Bellen, Bonno l   Verhamme, Peter m   Wells, Philip S n   Prandoni, Paolo o  


Author keywords

Antiplatelet agents; Deep vein thrombosis; Prevention; Pulmonary embolism; Venous thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; RIVAROXABAN; FIBRINOLYTIC AGENT;

EID: 84940654819     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH15-02-0131     Document Type: Article
Times cited : (54)

References (20)
  • 1
    • 84856802635 scopus 로고    scopus 로고
    • Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
    • Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141: e419S-494S.
    • (2012) Chest , vol.141
    • Kearon, C.1    Akl, E.A.2    Comerota, A.J.3
  • 2
    • 34249829228 scopus 로고    scopus 로고
    • The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients
    • Prandoni P, Noventa F, Ghirarduzzi A, et al. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. Haematologica 2007; 92: 199–205
    • (2007) Haematologica , vol.92 , pp. 199-205
    • Prandoni, P.1    Noventa, F.2    Ghirarduzzi, A.3
  • 3
    • 84908205835 scopus 로고    scopus 로고
    • Treatment patterns of venous thromboembolism in a real-world population: The Q-VTE study cohort
    • Tagalakis V, Patenaude V, Kahn SR, et al. Treatment patterns of venous thromboembolism in a real-world population: the Q-VTE study cohort. Thromb Res 2014; 134: 795–802
    • (2014) Thromb Res , vol.134 , pp. 795-802
    • Tagalakis, V.1    Patenaude, V.2    Kahn, S.R.3
  • 4
    • 84924869150 scopus 로고    scopus 로고
    • Duration of anticoagulation after venous thromboembolism in real world clinical practice
    • Ageno W, Samperiz A, Caballero R, et al. Duration of anticoagulation after venous thromboembolism in real world clinical practice. Thromb Res 2015; 135: 666–672
    • (2015) Thromb Res , vol.135 , pp. 666-672
    • Ageno, W.1    Samperiz, A.2    Caballero, R.3
  • 5
    • 84869441338 scopus 로고    scopus 로고
    • Low-dose aspirin for preventing recurrent venous thromboembolism
    • Brighton TA, Eikelboom JW, Mann K, et al. Low-dose aspirin for preventing recurrent venous thromboembolism. N Engl J Med 2012; 367: 1979–1987
    • (2012) N Engl J Med , vol.367 , pp. 1979-1987
    • Brighton, T.A.1    Eikelboom, J.W.2    Mann, K.3
  • 6
    • 84861402643 scopus 로고    scopus 로고
    • Aspirin for preventing the recurrence of venous thromboembolism
    • Becattini C, Agnelli G, Schenone A, et al. Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med 2012; 366: 1959–1967
    • (2012) N Engl J Med , vol.366 , pp. 1959-1967
    • Becattini, C.1    Agnelli, G.2    Schenone, A.3
  • 7
    • 84921536011 scopus 로고    scopus 로고
    • Aspirin for the prevention of recurrent venous thromboembolism: The INSPIRE collaboration
    • Simes J, Becattini C, Agnelli G, et al. Aspirin for the prevention of recurrent venous thromboembolism: the INSPIRE collaboration. Circulation 2014; 130: 1062–1071
    • (2014) Circulation , vol.130 , pp. 1062-1071
    • Simes, J.1    Becattini, C.2    Agnelli, G.3
  • 8
    • 84905977363 scopus 로고    scopus 로고
    • Evolving use of new oral anticoagulants for treatment of venous thromboembolism
    • Yeh CH, Gross PL, Weitz JI. Evolving use of new oral anticoagulants for treatment of venous thromboembolism. Blood 2014; 124: 1020–1028
    • (2014) Blood , vol.124 , pp. 1020-1028
    • Yeh, C.H.1    Gross, P.L.2    Weitz, J.I.3
  • 9
    • 84874003257 scopus 로고    scopus 로고
    • Extended use of dabigatran, warfarin, or placebo in venous thromboembolism
    • Schulman S, Kearon C, Kakkar AK, et al. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med 2013; 368: 709–718
    • (2013) N Engl J Med , vol.368 , pp. 709-718
    • Schulman, S.1    Kearon, C.2    Kakkar, A.K.3
  • 10
    • 78650619315 scopus 로고    scopus 로고
    • Oral rivaroxaban for symptomatic venous thromboembolism
    • EINSTEIN Investigators
    • EINSTEIN Investigators, Bauersachs R, Berkowitz SD, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363: 2499–2510
    • (2010) N Engl J Med , vol.363 , pp. 2499-2510
    • Bauersachs, R.1    Berkowitz, S.D.2
  • 11
    • 84873596181 scopus 로고    scopus 로고
    • Apixaban for extended treatment of venous thromboembolism
    • Agnelli G, Buller HR, Cohen A, et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med 2013; 368: 699–708
    • (2013) N Engl J Med , vol.368 , pp. 699-708
    • Agnelli, G.1    Buller, H.R.2    Cohen, A.3
  • 12
    • 84859385808 scopus 로고    scopus 로고
    • Oral rivaroxaban for the treatment of symptomatic pulmonary embolism
    • EINSTEIN Investigators
    • EINSTEIN Investigators, Buller HR, Prins MH, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012; 366: 1287–1297
    • (2012) N Engl J Med , vol.366 , pp. 1287-1297
    • Buller, H.R.1    Prins, M.H.2
  • 13
    • 84884336961 scopus 로고    scopus 로고
    • Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: A pooled analysis of the EINSTEIN-DVT and PE randomized studies
    • Prins MH, Lensing AW, Bauersachs R, et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J 2013; 11: 21
    • (2013) Thromb J , vol.11
    • Prins, M.H.1    Lensing, A.W.2    Bauersachs, R.3
  • 14
    • 84884874953 scopus 로고    scopus 로고
    • Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic deep-vein thrombosis
    • Bamber L, Wang MY, Prins MH, et al. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic deep-vein thrombosis. Thromb Haemost 2013; 110: 732–741
    • (2013) Thromb Haemost , vol.110 , pp. 732-741
    • Bamber, L.1    Wang, M.Y.2    Prins, M.H.3
  • 15
    • 84921454374 scopus 로고    scopus 로고
    • Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of pulmonary embolism; results from the EINSTEIN PE trial
    • Prins MH, Bamber L, Cano SJ, et al. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of pulmonary embolism; results from the EINSTEIN PE trial. Thromb Res 2015; 135: 281–288
    • (2015) Thromb Res , vol.135 , pp. 281-288
    • Prins, M.H.1    Bamber, L.2    Cano, S.J.3
  • 16
    • 65649094404 scopus 로고    scopus 로고
    • Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement
    • Eriksson BI, Kakkar AK, Turpie AG, et al. Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement. J Bone Joint Surgery Brit Vol 2009; 91: 636–644
    • (2009) J Bone Joint Surgery Brit Vol , vol.91 , pp. 636-644
    • Eriksson, B.I.1    Kakkar, A.K.2    Turpie, A.G.3
  • 17
    • 84873514413 scopus 로고    scopus 로고
    • Rivaroxaban for thromboprophylaxis in acutely ill medical patients
    • Cohen AT, Spiro TE, Buller HR, et al. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med 2013; 368: 513–523
    • (2013) N Engl J Med , vol.368 , pp. 513-523
    • Cohen, A.T.1    Spiro, T.E.2    Buller, H.R.3
  • 18
    • 0029590268 scopus 로고
    • Sample size calculation for complex clinical trials with survival endpoints
    • Shih JH. Sample size calculation for complex clinical trials with survival endpoints. Controlled Clin Trials 1995; 16: 395–407
    • (1995) Controlled Clin Trials , vol.16 , pp. 395-407
    • Shih, J.H.1
  • 19
    • 0042031415 scopus 로고    scopus 로고
    • Extended Low-Intensity Anticoagulation for Thrombo-Embolism I. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism
    • Kearon C, Ginsberg JS, Kovacs MJ, et al, Extended Low-Intensity Anticoagulation for Thrombo-Embolism I. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med 2003; 349: 631–699
    • (2003) N Engl J Med , vol.349 , pp. 631-699
    • Kearon, C.1    Ginsberg, J.S.2    Kovacs, M.J.3
  • 20
    • 0037431013 scopus 로고    scopus 로고
    • Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism
    • Ridker PM, Goldhaber SZ, Danielson E, et al. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med 2003; 348: 1425–1434.
    • (2003) N Engl J Med , vol.348 , pp. 1425-1434
    • Ridker, P.M.1    Goldhaber, S.Z.2    Danielson, E.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.